id,tokens,pred_labels,text,ner_tags,entities,pred_entities
2431,"['Default', 'Mode', 'Connectivity', 'in', 'Major', 'Depressive', 'Disorder', 'Measured', 'Up', 'to', '10', 'Days', 'After', 'Ketamine', 'Administration.^', '\n', 'BACKGROUND', ':', 'The', 'symptoms', 'of', 'major', 'depressive', 'disorder', '(', 'MDD', ')', 'are', 'rapidly', 'alleviated', 'by', 'administration', 'of', 'a', 'single', 'dose', 'of', 'the', 'glutamatergic', 'modulator', 'ketamine', '.', 'However', ',', 'few', 'studies', 'have', 'investigated', 'the', 'potential', 'sustained', 'neural', 'effects', 'of', 'this', 'agent', 'beyond', 'immediate', 'infusion', '.', 'This', 'study', 'used', 'functional', 'magnetic', 'resonance', 'imaging', 'to', 'examine', 'the', 'effect', 'of', 'a', 'single', 'ketamine', 'infusion', 'on', 'the', 'resting', 'state', 'default', 'mode', 'network', '(', 'DMN', ')', 'at', '2', 'and', '10', 'days', 'after', 'a', 'single', 'ketamine', 'infusion', 'in', 'unmedicated', 'subjects', 'with', 'MDD', 'as', 'well', 'as', 'healthy', 'control', 'subjects', '(', 'HCs', ')', '.', 'METHODS', ':', 'Data', 'were', 'drawn', 'from', 'a', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'crossover', 'study', 'of', '58', 'participants', '(', '33', 'with', 'MDD', 'and', '25', 'HCs', ')', 'who', 'received', 'an', 'intravenous', 'infusion', 'of', 'either', 'ketamine', 'hydrochloride', '(', '0.5', 'mg', '/', 'kg', ')', 'or', 'placebo', 'on', '2', 'separate', 'test', 'days', 'spaced', '2', 'weeks', 'apart', '.', 'Eight', 'minutes', 'of', 'functional', 'magnetic', 'resonance', 'imaging', 'resting', 'state', 'data', 'was', 'acquired', 'at', 'baseline', 'and', 'at', 'about', '2', 'and', '10', 'days', 'after', 'both', 'infusions', '.', 'The', 'DMN', 'was', 'defined', 'using', 'seed', '-', 'based', 'correlation', 'and', 'was', 'compared', 'across', 'groups', 'and', 'scans', '.', 'RESULTS', ':', 'In', 'subjects', 'with', 'MDD', ',', 'connectivity', 'between', 'the', 'insula', 'and', 'the', 'DMN', 'was', 'normalized', 'compared', 'with', 'HCs', '2', 'days', 'postketamine', 'infusion', '.', 'This', 'change', 'was', 'reversed', 'after', '10', 'days', 'and', 'did', 'not', 'appear', 'in', 'either', 'of', 'the', 'placebo', 'scans', '.', 'Group', '-', 'specific', 'connectivity', 'differences', 'in', 'drug', 'response', 'were', 'observed', ',', 'most', 'notably', 'in', 'the', 'insula', 'in', 'subjects', 'with', 'MDD', 'and', 'in', 'the', 'thalamus', 'in', 'HCs', '.', 'CONCLUSIONS', ':', 'Connectivity', 'changes', 'in', 'the', 'insula', 'in', 'subjects', 'with', 'MDD', 'suggest', 'that', 'ketamine', 'may', 'normalize', 'the', 'interaction', 'between', 'the', 'DMN', 'and', 'salience', 'networks', ',', 'supporting', 'the', 'triple', 'network', 'dysfunction', 'model', 'of', 'MDD', '.']","['O', 'I-Application area', 'I-Application area', 'B-Dosage', 'O', 'B-Dosage', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'I-Dosage', 'I-Application area', 'I-Dosage', 'O', 'O', 'I-Application area', 'B-Application area', 'B-Dosage', 'B-Application area', 'B-Dosage', 'I-Application area', 'I-Application area', 'O', 'B-Dosage', 'B-Application area', 'B-Application area', 'B-Application area', 'B-Application area', 'I-Dosage', 'O', 'B-Application area', 'B-Application area', 'B-Dosage', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'B-Application area', 'B-Application area', 'B-Dosage', 'B-Application area', 'O', 'B-Application area', 'B-Application area', 'I-Dosage', 'I-Dosage', 'O', 'B-Dosage', 'B-Application area', 'B-Dosage', 'I-Application area', 'I-Application area', 'B-Dosage', 'O', 'I-Application area', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'B-Application area', 'B-Application area', 'I-Application area', 'B-Dosage', 'O', 'B-Application area', 'B-Application area', 'I-Dosage', 'B-Dosage', 'I-Application area', 'B-Application area', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Dosage', 'B-Dosage', 'O', 'O', 'B-Application area', 'B-Dosage', 'O', 'B-Application area', 'B-Application area', 'I-Dosage', 'B-Dosage', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'I-Application area', 'B-Application area', 'O', 'O', 'O', 'O', 'I-Application area', 'I-Application area', 'O', 'B-Dosage', 'O', 'O', 'B-Application area', 'O', 'B-Application area', 'B-Dosage', 'I-Dosage', 'B-Application area', 'B-Application area', 'B-Application area', 'I-Application area', 'B-Application area', 'B-Dosage', 'B-Application area', 'I-Application area', 'I-Application area', 'B-Application area', 'B-Application area', 'B-Application area', 'B-Dosage', 'B-Dosage', 'B-Application area', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Dosage', 'B-Dosage', 'B-Application area', 'I-Dosage', 'B-Dosage', 'O', 'B-Dosage', 'B-Application area', 'B-Application area', 'B-Application area', 'I-Dosage', 'B-Application area', 'O', 'O', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Application area', 'B-Dosage', 'B-Dosage', 'I-Application area', 'B-Dosage', 'O', 'O', 'B-Dosage', 'B-Application area', 'B-Application area', 'B-Dosage', 'O', 'I-Application area', 'I-Dosage', 'I-Application area', 'I-Application area', 'I-Dosage', 'I-Application area', 'I-Dosage', 'O', 'I-Application area', 'O', 'B-Application area', 'B-Dosage', 'B-Dosage', 'O', 'I-Dosage', 'B-Dosage', 'O', 'B-Application area', 'B-Dosage', 'O', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'O', 'I-Application area', 'O', 'O', 'O', 'I-Application area', 'I-Application area', 'B-Dosage', 'I-Application area', 'B-Dosage', 'O', 'I-Application area', 'I-Dosage', 'B-Dosage', 'I-Application area', 'O', 'I-Application area', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'B-Application area', 'B-Application area', 'B-Application area', 'B-Application area', 'B-Application area', 'O', 'I-Application area', 'I-Application area', 'I-Dosage', 'B-Application area', 'O', 'I-Application area', 'O', 'I-Application area', 'B-Dosage', 'O', 'I-Application area', 'O', 'O', 'I-Application area', 'O', 'O', 'B-Dosage', 'B-Application area', 'B-Application area', 'I-Application area', 'I-Dosage', 'I-Application area', 'I-Application area', 'B-Application area', 'B-Application area', 'B-Dosage', 'B-Dosage', 'I-Application area', 'O', 'I-Dosage', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'I-Application area', 'I-Dosage', 'B-Dosage', 'B-Dosage', 'B-Application area', 'I-Application area', 'B-Application area', 'I-Application area', 'B-Application area', 'I-Application area', 'B-Application area', 'O', 'B-Application area', 'B-Application area', 'B-Application area', 'I-Application area', 'B-Application area', 'B-Dosage', 'I-Dosage', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Dosage', 'B-Application area', 'B-Application area', 'I-Dosage', 'B-Application area', 'I-Application area', 'B-Application area', 'O', 'B-Application area', 'I-Application area', 'I-Dosage', 'I-Application area', 'B-Application area', 'O', 'B-Application area', 'I-Application area', 'B-Application area', 'O', 'I-Application area', 'I-Application area', 'B-Application area', 'I-Application area', 'B-Application area', 'O', 'B-Application area', 'O', 'O', 'I-Dosage', 'B-Application area', 'O', 'I-Dosage']","Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration.^
BACKGROUND: The symptoms of major depressive disorder (MDD) are rapidly alleviated by administration of a single dose of the glutamatergic modulator ketamine. However, few studies have investigated the potential sustained neural effects of this agent beyond immediate infusion. This study used functional magnetic resonance imaging to examine the effect of a single ketamine infusion on the resting state default mode network (DMN) at 2 and 10 days after a single ketamine infusion in unmedicated subjects with MDD as well as healthy control subjects (HCs). METHODS: Data were drawn from a double-blind, placebo-controlled crossover study of 58 participants (33 with MDD and 25 HCs) who received an intravenous infusion of either ketamine hydrochloride (0.5 mg/kg) or placebo on 2 separate test days spaced 2 weeks apart. Eight minutes of functional magnetic resonance imaging resting state data was acquired at baseline and at about 2 and 10 days after both infusions. The DMN was defined using seed-based correlation and was compared across groups and scans. RESULTS: In subjects with MDD, connectivity between the insula and the DMN was normalized compared with HCs 2 days postketamine infusion. This change was reversed after 10 days and did not appear in either of the placebo scans. Group-specific connectivity differences in drug response were observed, most notably in the insula in subjects with MDD and in the thalamus in HCs. CONCLUSIONS: Connectivity changes in the insula in subjects with MDD suggest that ketamine may normalize the interaction between the DMN and salience networks, supporting the triple network dysfunction model of MDD.","['O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']","[('Major Depressive Disorder', 'application-area'), ('major depressive disorder', 'application-area'), ('MDD', 'application-area'), ('0.5 mg/kg', 'dosage')]","[('in', 'dosage'), ('Depressive Disorder', 'dosage'), ('symptoms', 'application-area'), ('of', 'dosage'), ('major', 'application-area'), ('depressive disorder (', 'dosage'), (')', 'dosage'), ('are', 'application-area'), ('rapidly', 'application-area'), ('alleviated', 'application-area'), ('by administration', 'application-area'), ('a', 'application-area'), ('single', 'application-area'), ('dose', 'dosage'), ('of the glutamatergic modulator ketamine. However', 'application-area'), (',', 'application-area'), ('few', 'application-area'), ('studies', 'dosage'), ('have', 'application-area'), ('the', 'application-area'), ('potential sustained neural', 'application-area'), ('of', 'dosage'), ('this', 'application-area'), ('agent beyond immediate', 'dosage'), ('infusion', 'dosage'), ('study used functional magnetic resonance imaging', 'application-area'), ('to', 'application-area'), ('examine the', 'application-area'), ('effect', 'dosage'), ('a', 'application-area'), ('single ketamine', 'application-area'), ('infusion on', 'dosage'), ('the', 'application-area'), ('state default mode network (', 'application-area'), (')', 'dosage'), ('at', 'dosage'), ('10', 'application-area'), ('days', 'dosage'), ('a', 'application-area'), ('single ketamine', 'application-area'), ('infusion in unmedicated subjects', 'dosage'), ('as', 'application-area'), (')', 'dosage'), (':', 'application-area'), ('were', 'application-area'), ('drawn from', 'dosage'), ('a', 'application-area'), ('double', 'application-area'), ('-blind', 'application-area'), (',', 'application-area'), ('placebo', 'dosage'), ('-controlled crossover', 'application-area'), ('study', 'application-area'), ('of', 'application-area'), ('58', 'application-area'), ('participants', 'dosage'), ('(', 'dosage'), ('33', 'application-area'), ('with MDD and', 'application-area'), ('HCs', 'dosage'), (')', 'dosage'), ('who received', 'application-area'), ('an', 'dosage'), ('infusion', 'dosage'), ('of', 'application-area'), ('either', 'application-area'), ('ketamine hydrochloride', 'application-area'), ('(', 'application-area'), ('/', 'dosage'), ('kg', 'dosage'), (')', 'dosage'), ('or', 'application-area'), ('placebo', 'dosage'), ('on 2', 'dosage'), ('separate', 'dosage'), ('spaced', 'dosage'), ('2', 'application-area'), ('weeks', 'application-area'), ('apart', 'dosage'), ('was', 'application-area'), ('acquired', 'dosage'), ('at', 'dosage'), ('at', 'dosage'), ('2', 'application-area'), ('and', 'dosage'), ('days', 'dosage'), ('after', 'dosage'), ('both', 'dosage'), ('infusions', 'dosage'), ('-based', 'dosage'), ('correlation', 'dosage'), ('across groups', 'dosage'), ('In subjects with MDD, connectivity', 'application-area'), ('between', 'application-area'), ('the', 'application-area'), ('insula', 'application-area'), ('and', 'application-area'), ('the', 'application-area'), ('with', 'application-area'), ('infusion', 'dosage'), ('days', 'dosage'), ('and', 'application-area'), ('did not appear in either', 'application-area'), ('of', 'application-area'), ('the', 'application-area'), ('placebo', 'dosage'), ('scans.', 'dosage'), (',', 'dosage'), ('most', 'dosage'), ('notably in', 'application-area'), ('the insula', 'application-area'), ('in subjects', 'application-area'), ('with', 'application-area'), ('and', 'application-area'), ('in', 'application-area'), ('the thalamus', 'application-area'), ('in', 'application-area'), ('HCs.', 'dosage'), ('CONCLUSIONS: Connectivity changes', 'application-area'), ('in', 'application-area'), ('the insula', 'application-area'), ('in subjects', 'application-area'), ('with', 'application-area'), ('suggest that ketamine may', 'application-area'), ('normalize', 'application-area'), ('interaction between', 'application-area'), ('the', 'application-area'), ('networks,', 'application-area'), ('supporting', 'application-area'), ('triple', 'application-area'), ('of', 'application-area')]"
933,"['Resting', '-', 'state', 'Network', '-', 'specific', 'Breakdown', 'of', 'Functional', 'Connectivity', 'during', 'Ketamine', 'Alteration', 'of', 'Consciousness', 'in', 'Volunteers.^', '\n', 'BACKGROUND', ':', 'Consciousness', '-', 'altering', 'anesthetic', 'agents', 'disturb', 'connectivity', 'between', 'brain', 'regions', 'composing', 'the', 'resting', '-', 'state', 'consciousness', 'networks', '(', 'RSNs', ')', '.', 'The', 'default', 'mode', 'network', '(', 'DMn', ')', ',', 'executive', 'control', 'network', ',', 'salience', 'network', '(', 'SALn', ')', ',', 'auditory', 'network', ',', 'sensorimotor', 'network', '(', 'SMn', ')', ',', 'and', 'visual', 'network', 'sustain', 'mentation', '.', 'Ketamine', 'modifies', 'consciousness', 'differently', 'from', 'other', 'agents', ',', 'producing', 'psychedelic', 'dreaming', 'and', 'no', 'apparent', 'interaction', 'with', 'the', 'environment', '.', 'The', 'authors', 'used', 'functional', 'magnetic', 'resonance', 'imaging', 'to', 'explore', 'ketamine', '-', 'induced', 'changes', 'in', 'RSNs', 'connectivity', '.', 'METHODS', ':', 'Fourteen', 'healthy', 'volunteers', 'received', 'stepwise', 'intravenous', 'infusions', 'of', 'ketamine', 'up', 'to', 'loss', 'of', 'responsiveness', '.', 'Because', 'of', 'agitation', ',', 'data', 'from', 'six', 'subjects', 'were', 'excluded', 'from', 'analysis', '.', 'RSNs', 'connectivity', 'was', 'compared', 'between', 'absence', 'of', 'ketamine', '(', 'wake', 'state', '[', 'W1', ']', ')', ',', 'light', 'ketamine', 'sedation', ',', 'and', 'ketamine', '-', 'induced', 'unresponsiveness', '(', 'deep', 'sedation', '[', 'S2', ']', ')', '.', 'RESULTS', ':', 'Increasing', 'the', 'depth', 'of', 'ketamine', 'sedation', 'from', 'W1', 'to', 'S2', 'altered', 'DMn', 'and', 'SALn', 'connectivity', 'and', 'suppressed', 'the', 'anticorrelated', 'activity', 'between', 'DMn', 'and', 'other', 'brain', 'regions', '.', 'During', 'S2', ',', 'DMn', 'connectivity', ',', 'particularly', 'between', 'the', 'medial', 'prefrontal', 'cortex', 'and', 'the', 'remaining', 'network', '(', 'effect', 'size', 'β', '[', '95', '%', 'CI', ']', ':', 'W1', '=', '0.20', '[', '0.18', 'to', '0.22', ']', ';', 'S2', '=', '0.07', '[', '0.04', 'to', '0.09', ']', ')', ',', 'and', 'DMn', 'anticorrelated', 'activity', '(', 'e.g.', ',', 'right', 'sensory', 'cortex', ':', 'W1', '=', '-0.07', '[', '-0.09', 'to', '-0.04', ']', ';', 'S2', '=', '0.04', '[', '0.01', 'to', '0.06', ']', ')', 'were', 'broken', 'down', '.', 'SALn', 'connectivity', 'was', 'nonuniformly', 'suppressed', '(', 'e.g.', ',', 'left', 'parietal', 'operculum', ':', 'W1', '=', '0.08', '[', '0.06', 'to', '0.09', ']', ';', 'S2', '=', '0.05', '[', '0.02', 'to', '0.07', ']', ')', '.', 'Executive', 'control', 'networks', ',', 'auditory', 'network', ',', 'SMn', ',', 'and', 'visual', 'network', 'were', 'minimally', 'affected', '.', 'CONCLUSIONS', ':', 'Ketamine', 'induces', 'specific', 'changes', 'in', 'connectivity', 'within', 'and', 'between', 'RSNs', '.', 'Breakdown', 'of', 'frontoparietal', 'DMn', 'connectivity', 'and', 'DMn', 'anticorrelation', 'and', 'sensory', 'and', 'SMn', 'connectivity', 'preservation', 'are', 'common', 'to', 'ketamine', 'and', 'propofol', '-', 'induced', 'alterations', 'of', 'consciousness', '.']","['I-Dosage', 'I-Dosage', 'I-Application area', 'I-Application area', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'I-Dosage', 'I-Dosage', 'O', 'B-Dosage', 'B-Dosage', 'I-Application area', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'B-Dosage', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'B-Dosage', 'I-Application area', 'O', 'O', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Dosage', 'O', 'I-Application area', 'I-Application area', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Dosage', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'B-Application area', 'I-Dosage', 'O', 'B-Dosage', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Dosage', 'B-Application area', 'I-Dosage', 'I-Application area', 'I-Application area', 'I-Application area', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'I-Application area', 'I-Application area', 'B-Dosage', 'B-Dosage', 'B-Application area', 'I-Application area', 'B-Dosage', 'B-Application area', 'I-Application area', 'B-Dosage', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'I-Application area', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Dosage', 'I-Application area', 'I-Application area', 'B-Application area', 'B-Application area', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'I-Application area', 'O', 'I-Application area', 'B-Dosage', 'O', 'I-Dosage', 'I-Application area', 'B-Application area', 'I-Application area', 'B-Dosage', 'B-Application area', 'O', 'B-Dosage', 'O', 'I-Dosage', 'B-Dosage', 'B-Application area', 'O', 'B-Application area', 'I-Application area', 'B-Dosage', 'O', 'O', 'B-Dosage', 'I-Application area', 'O', 'I-Dosage', 'B-Dosage', 'O', 'B-Application area', 'I-Dosage', 'I-Dosage', 'I-Application area', 'O', 'O', 'I-Application area', 'I-Application area', 'I-Dosage', 'O', 'I-Application area', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'I-Dosage', 'B-Dosage', 'O', 'B-Dosage', 'I-Application area', 'I-Dosage', 'I-Dosage', 'B-Dosage', 'B-Dosage', 'I-Dosage', 'B-Dosage', 'I-Dosage', 'I-Application area', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'O', 'I-Dosage', 'I-Dosage', 'B-Dosage', 'O', 'O', 'B-Dosage', 'B-Application area', 'O', 'B-Dosage', 'B-Dosage', 'I-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Application area', 'I-Dosage', 'B-Application area', 'B-Application area', 'I-Application area', 'B-Dosage', 'I-Application area', 'I-Dosage', 'I-Application area', 'I-Application area', 'I-Dosage', 'B-Application area', 'I-Application area', 'B-Dosage', 'I-Application area', 'I-Application area', 'B-Dosage', 'I-Application area', 'I-Dosage', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'B-Dosage', 'I-Application area', 'I-Application area', 'O', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'I-Application area', 'I-Application area', 'B-Application area', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'B-Dosage', 'O', 'O', 'B-Dosage', 'O', 'O', 'O', 'B-Application area', 'B-Dosage', 'I-Dosage', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'I-Dosage', 'B-Application area', 'O', 'I-Dosage', 'O', 'I-Application area', 'I-Application area', 'B-Application area', 'I-Dosage', 'I-Application area', 'I-Dosage', 'O', 'I-Application area', 'O', 'I-Dosage', 'I-Dosage', 'I-Application area', 'O', 'I-Dosage', 'B-Dosage', 'O', 'B-Dosage', 'B-Application area', 'O', 'I-Dosage', 'I-Application area', 'I-Application area', 'I-Dosage', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Dosage', 'I-Dosage', 'O', 'B-Application area', 'O', 'I-Dosage', 'I-Application area', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'I-Application area', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'I-Dosage', 'B-Application area', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'B-Application area', 'I-Dosage', 'I-Application area', 'I-Application area', 'I-Dosage', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Dosage', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'I-Application area', 'I-Dosage', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Dosage', 'I-Application area', 'B-Application area', 'I-Dosage', 'I-Dosage', 'I-Application area', 'I-Dosage', 'B-Application area', 'I-Application area', 'I-Application area', 'B-Application area', 'B-Dosage', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'B-Dosage', 'I-Application area', 'B-Dosage', 'I-Application area', 'I-Dosage', 'B-Dosage', 'I-Dosage', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'B-Application area', 'B-Dosage', 'I-Dosage']","Resting-state Network-specific Breakdown of Functional Connectivity during Ketamine Alteration of Consciousness in Volunteers.^
BACKGROUND: Consciousness-altering anesthetic agents disturb connectivity between brain regions composing the resting-state consciousness networks (RSNs). The default mode network (DMn), executive control network, salience network (SALn), auditory network, sensorimotor network (SMn), and visual network sustain mentation. Ketamine modifies consciousness differently from other agents, producing psychedelic dreaming and no apparent interaction with the environment. The authors used functional magnetic resonance imaging to explore ketamine-induced changes in RSNs connectivity. METHODS: Fourteen healthy volunteers received stepwise intravenous infusions of ketamine up to loss of responsiveness. Because of agitation, data from six subjects were excluded from analysis. RSNs connectivity was compared between absence of ketamine (wake state [W1]), light ketamine sedation, and ketamine-induced unresponsiveness (deep sedation [S2]). RESULTS: Increasing the depth of ketamine sedation from W1 to S2 altered DMn and SALn connectivity and suppressed the anticorrelated activity between DMn and other brain regions. During S2, DMn connectivity, particularly between the medial prefrontal cortex and the remaining network (effect size β [95% CI]: W1 = 0.20 [0.18 to 0.22]; S2 = 0.07 [0.04 to 0.09]), and DMn anticorrelated activity (e.g., right sensory cortex: W1 = -0.07 [-0.09 to -0.04]; S2 = 0.04 [0.01 to 0.06]) were broken down. SALn connectivity was nonuniformly suppressed (e.g., left parietal operculum: W1 = 0.08 [0.06 to 0.09]; S2 = 0.05 [0.02 to 0.07]). Executive control networks, auditory network, SMn, and visual network were minimally affected. CONCLUSIONS: Ketamine induces specific changes in connectivity within and between RSNs. Breakdown of frontoparietal DMn connectivity and DMn anticorrelation and sensory and SMn connectivity preservation are common to ketamine and propofol-induced alterations of consciousness.","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",[],"[('Consciousness', 'dosage'), ('in Volunteers.^ BACKGROUND:', 'dosage'), ('Consciousness-altering', 'dosage'), ('anesthetic', 'dosage'), ('agents disturb connectivity between brain regions', 'application-area'), ('composing the', 'dosage'), (')', 'dosage'), ('mode network (', 'application-area'), ('), executive control network, salience', 'dosage'), ('network (', 'application-area'), ('), auditory network, sensorimotor network (', 'dosage'), ('SMn), and visual', 'application-area'), ('network sustain mentation. Ketamine modifies consciousness differently from other', 'application-area'), ('agents', 'dosage'), (',', 'dosage'), ('producing psychedelic', 'application-area'), ('dreaming', 'dosage'), ('and no', 'application-area'), ('apparent interaction with the', 'dosage'), ('authors used functional magnetic resonance imaging', 'application-area'), ('to', 'application-area'), ('explore ketamine-induced', 'application-area'), ('.', 'dosage'), ('healthy volunteers', 'application-area'), ('received', 'dosage'), ('stepwise', 'application-area'), ('infusions', 'dosage'), ('up', 'dosage'), ('to', 'application-area'), ('of responsiveness', 'application-area'), ('.', 'dosage'), ('agitation,', 'dosage'), ('six', 'dosage'), ('were excluded from analysis', 'application-area'), ('of ketamine (', 'dosage'), (']', 'dosage'), (', light ketamine sedation', 'dosage'), (',', 'dosage'), ('and ketamine', 'dosage'), ('-induced unresponsiveness', 'dosage'), ('(', 'dosage'), ('deep', 'dosage'), ('sedation', 'dosage'), (')', 'dosage'), (':', 'dosage'), ('Increasing', 'application-area'), ('depth', 'dosage'), ('of ketamine', 'dosage'), ('sedation', 'dosage'), ('from', 'dosage'), ('W1', 'dosage'), ('to S2', 'application-area'), ('altered', 'application-area'), ('DMn and', 'application-area'), ('SALn connectivity and suppressed the anticorrelated', 'dosage'), ('activity between', 'application-area'), ('DMn and other', 'dosage'), ('brain regions.', 'dosage'), ('During S2, DMn connectivity', 'application-area'), (', particularly between', 'dosage'), ('remaining', 'application-area'), ('network (', 'dosage'), ('[', 'application-area'), (']', 'dosage'), ('=', 'dosage'), ('to', 'application-area'), ('0.22]; S2', 'dosage'), ('to', 'application-area'), ('DMn anticorrelated activity (', 'application-area'), ('-0.07', 'dosage'), ('-0.09', 'dosage'), ('to', 'application-area'), ('0.06]) were broken down', 'dosage'), (',', 'application-area'), ('0.09]; S2', 'dosage'), ('to', 'application-area'), ('0.07]). Executive control networks, auditory network,', 'dosage'), ('SMn, and visual network', 'application-area'), ('were minimally affected.', 'application-area'), ('CONCLUSIONS: Ketamine induces specific changes in connectivity within and between', 'dosage'), ('RSNs. Breakdown of frontoparietal', 'application-area'), ('DMn connectivity and', 'application-area'), ('DMn', 'application-area'), ('anticorrelation and sensory and SMn connectivity', 'dosage'), ('preservation are', 'dosage'), ('common to ketamine', 'dosage'), ('and propofol', 'dosage'), ('-induced alterations', 'dosage'), ('of', 'application-area')]"
8870,"['Oxytocin', 'receptor', 'gene', 'variations', 'and', 'socio', '-', 'emotional', 'effects', 'of', 'MDMA', ':', 'A', 'pooled', 'analysis', 'of', 'controlled', 'studies', 'in', 'healthy', 'subjects.^', '\n', 'Methylenedioxymethamphetamine', '(', 'MDMA', ')', 'increases', 'oxytocin', ',', 'empathy', ',', 'and', 'prosociality', '.', 'Oxytocin', 'plays', 'a', 'critical', 'role', 'in', 'emotion', 'processing', 'and', 'social', 'behavior', 'and', 'has', 'been', 'shown', 'to', 'mediate', 'the', 'prosocial', 'effects', 'of', 'MDMA', 'in', 'animals', '.', 'Genetic', 'variants', ',', 'such', 'as', 'single', '-', 'nucleotide', 'polymorphisms', '(', 'SNPs', ')', ',', 'of', 'the', 'oxytocin', 'receptor', '(', 'OXTR', ')', 'may', 'influence', 'the', 'emotional', 'and', 'social', 'effects', 'of', 'MDMA', 'in', 'humans', '.', 'The', 'effects', 'of', 'common', 'genetic', 'variants', 'of', 'the', 'OXTR', '(', 'rs53576', ',', 'rs1042778', ',', 'and', 'rs2254298', 'SNPs', ')', 'on', 'the', 'emotional', ',', 'empathogenic', ',', 'and', 'prosocial', 'effects', 'of', 'MDMA', 'were', 'characterized', 'in', 'up', 'to', '132', 'healthy', 'subjects', 'in', 'a', 'pooled', 'analysis', 'of', 'eight', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'studies', '.', 'In', 'a', 'subset', 'of', '53', 'subjects', ',', 'MDMA', 'produced', 'significantly', 'greater', 'feelings', 'of', 'trust', 'in', 'rs1042778', 'TT', 'genotypes', 'compared', 'with', 'G', 'allele', 'carriers', '.', 'The', 'rs53576', 'and', 'rs225498', 'SNPs', 'did', 'not', 'moderate', 'the', 'subjective', 'effects', 'of', 'MDMA', 'in', 'up', 'to', '132', 'subjects', '.', 'None', 'of', 'the', 'SNPs', 'moderated', 'MDMA', '-', 'induced', 'impairments', 'in', 'negative', 'facial', 'emotion', 'recognition', 'or', 'enhancements', 'in', 'emotional', 'empathy', 'in', 'the', 'Multifaceted', 'Empathy', 'Test', 'in', '69', 'subjects', '.', 'MDMA', 'significantly', 'increased', 'plasma', 'oxytocin', 'concentrations', '.', 'MDMA', 'and', 'oxytocin', 'concentrations', 'did', 'not', 'differ', 'between', 'OXTR', 'gene', 'variants', '.', 'The', 'present', 'results', 'provide', 'preliminary', 'evidence', 'that', 'OXTR', 'gene', 'variations', 'may', 'modulate', 'aspects', 'of', 'the', 'prosocial', 'subjective', 'effects', 'of', 'MDMA', 'in', 'humans', '.', 'However', ',', 'interpretation', 'should', 'be', 'cautious', 'due', 'to', 'the', 'small', 'sample', 'size', '.', 'Additionally', ',', 'OXTR', 'SNPs', 'did', 'not', 'moderate', 'the', 'subjective', 'overall', 'effect', 'of', 'MDMA', '(', 'any', 'drug', 'effect', ')', 'or', 'feelings', 'of', '""', 'closeness', 'to', 'others', '""', '.', 'TRIAL', 'REGISTRATION', ':', 'ClinicalTrials.gov', ':', 'http://www.clinicaltrials.gov', ',', 'No', ':', 'NCT00886886', ',', 'NCT00990067', ',', 'NCT01136278', ',', 'NCT01270672', ',', 'NCT01386177', ',', 'NCT01465685', ',', 'NCT01771874', ',', 'and', 'NCT01951508', '.']","['I-Application area', 'I-Application area', 'O', 'I-Application area', 'B-Dosage', 'B-Dosage', 'I-Application area', 'I-Application area', 'I-Application area', 'B-Application area', 'B-Dosage', 'I-Dosage', 'O', 'I-Dosage', 'I-Application area', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'B-Application area', 'I-Application area', 'I-Dosage', 'I-Application area', 'I-Application area', 'B-Dosage', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'B-Dosage', 'I-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'I-Dosage', 'I-Application area', 'I-Dosage', 'B-Application area', 'I-Application area', 'I-Dosage', 'B-Dosage', 'I-Application area', 'I-Application area', 'B-Dosage', 'I-Application area', 'I-Application area', 'B-Application area', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'B-Application area', 'I-Application area', 'B-Dosage', 'I-Application area', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'I-Application area', 'I-Dosage', 'I-Application area', 'O', 'B-Dosage', 'O', 'O', 'I-Application area', 'I-Application area', 'B-Dosage', 'I-Application area', 'I-Application area', 'O', 'O', 'B-Application area', 'B-Application area', 'B-Application area', 'I-Dosage', 'I-Application area', 'I-Application area', 'I-Dosage', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Dosage', 'B-Dosage', 'B-Dosage', 'I-Application area', 'B-Application area', 'B-Dosage', 'I-Application area', 'I-Application area', 'I-Dosage', 'O', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Dosage', 'I-Application area', 'I-Application area', 'B-Application area', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'B-Dosage', 'O', 'O', 'O', 'B-Dosage', 'B-Application area', 'B-Application area', 'I-Dosage', 'B-Dosage', 'I-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'I-Application area', 'B-Application area', 'B-Dosage', 'B-Application area', 'I-Dosage', 'I-Application area', 'B-Dosage', 'I-Application area', 'O', 'B-Application area', 'O', 'B-Application area', 'B-Application area', 'I-Dosage', 'I-Application area', 'B-Application area', 'I-Application area', 'I-Application area', 'B-Application area', 'I-Application area', 'B-Application area', 'B-Application area', 'O', 'I-Application area', 'I-Application area', 'I-Dosage', 'B-Application area', 'B-Application area', 'I-Dosage', 'B-Application area', 'B-Dosage', 'I-Application area', 'B-Dosage', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Application area', 'B-Application area', 'I-Application area', 'B-Dosage', 'B-Application area', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'I-Application area', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'I-Application area', 'I-Dosage', 'I-Application area', 'B-Application area', 'B-Dosage', 'I-Application area', 'B-Application area', 'B-Dosage', 'I-Application area', 'B-Dosage', 'I-Application area', 'O', 'I-Application area', 'I-Dosage', 'I-Application area', 'B-Application area', 'O', 'O', 'I-Dosage', 'B-Dosage', 'B-Dosage', 'I-Application area', 'I-Application area', 'I-Application area', 'B-Application area', 'B-Application area', 'B-Dosage', 'B-Dosage', 'I-Application area', 'I-Application area', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Application area', 'O', 'I-Application area', 'I-Dosage', 'I-Application area', 'B-Dosage', 'B-Dosage', 'I-Application area', 'I-Dosage', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'B-Dosage', 'I-Dosage', 'B-Dosage', 'B-Dosage', 'I-Dosage', 'B-Dosage', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Dosage', 'O', 'I-Application area', 'I-Dosage', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'B-Dosage', 'B-Application area', 'I-Dosage', 'O', 'I-Application area', 'I-Application area', 'I-Dosage', 'B-Dosage', 'B-Dosage', 'B-Application area', 'B-Dosage', 'B-Dosage', 'I-Application area', 'B-Application area', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Dosage', 'I-Application area', 'B-Dosage', 'B-Dosage', 'B-Application area', 'B-Application area', 'B-Dosage', 'I-Application area', 'O', 'O', 'B-Application area', 'O', 'I-Application area', 'I-Dosage', 'I-Application area', 'B-Application area', 'I-Dosage', 'O', 'I-Dosage', 'I-Dosage', 'I-Application area', 'I-Application area', 'B-Dosage', 'I-Application area', 'B-Dosage', 'I-Application area', 'B-Dosage', 'I-Application area', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'O', 'O', 'B-Dosage', 'I-Dosage', 'B-Application area', 'O', 'I-Application area', 'B-Application area', 'B-Application area', 'B-Application area', 'B-Application area', 'I-Application area', 'B-Application area', 'B-Application area', 'B-Application area', 'O', 'B-Application area', 'B-Application area', 'B-Application area', 'B-Dosage', 'B-Application area', 'B-Dosage', 'O', 'B-Dosage', 'O', 'B-Dosage', 'B-Application area', 'B-Dosage', 'O', 'B-Dosage', 'O', 'B-Application area', 'B-Dosage', 'I-Dosage']","Oxytocin receptor gene variations and socio-emotional effects of MDMA: A pooled analysis of controlled studies in healthy subjects.^
Methylenedioxymethamphetamine (MDMA) increases oxytocin, empathy, and prosociality. Oxytocin plays a critical role in emotion processing and social behavior and has been shown to mediate the prosocial effects of MDMA in animals. Genetic variants, such as single-nucleotide polymorphisms (SNPs), of the oxytocin receptor (OXTR) may influence the emotional and social effects of MDMA in humans. The effects of common genetic variants of the OXTR (rs53576, rs1042778, and rs2254298 SNPs) on the emotional, empathogenic, and prosocial effects of MDMA were characterized in up to 132 healthy subjects in a pooled analysis of eight double-blind, placebo-controlled studies. In a subset of 53 subjects, MDMA produced significantly greater feelings of trust in rs1042778 TT genotypes compared with G allele carriers. The rs53576 and rs225498 SNPs did not moderate the subjective effects of MDMA in up to 132 subjects. None of the SNPs moderated MDMA-induced impairments in negative facial emotion recognition or enhancements in emotional empathy in the Multifaceted Empathy Test in 69 subjects. MDMA significantly increased plasma oxytocin concentrations. MDMA and oxytocin concentrations did not differ between OXTR gene variants. The present results provide preliminary evidence that OXTR gene variations may modulate aspects of the prosocial subjective effects of MDMA in humans. However, interpretation should be cautious due to the small sample size. Additionally, OXTR SNPs did not moderate the subjective overall effect of MDMA (any drug effect) or feelings of ""closeness to others"". TRIAL REGISTRATION: ClinicalTrials.gov: http://www.clinicaltrials.gov, No: NCT00886886, NCT00990067, NCT01136278, NCT01270672, NCT01386177, NCT01465685, NCT01771874, and NCT01951508.","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",[],"[('and', 'dosage'), ('socio-emotional effects', 'dosage'), ('of', 'application-area'), ('MDMA:', 'dosage'), ('of controlled studies in', 'application-area'), ('healthy subjects.^ Methylenedioxymethamphetamine (', 'application-area'), ('MDMA', 'dosage'), (') increases oxytocin', 'dosage'), (', empathy', 'dosage'), (',', 'dosage'), ('and', 'dosage'), ('prosociality. Oxytocin plays', 'dosage'), ('a critical role', 'application-area'), ('in emotion processing', 'dosage'), ('and social behavior', 'dosage'), ('and', 'application-area'), ('has been shown to', 'application-area'), ('mediate the', 'application-area'), ('prosocial effects', 'dosage'), ('of', 'dosage'), ('MDMA', 'dosage'), ('in animals. Genetic', 'dosage'), (',', 'dosage'), ('nucleotide polymorphisms (', 'dosage'), (',', 'application-area'), ('of', 'application-area'), ('the oxytocin receptor (OXTR', 'application-area'), (') may influence the emotional', 'application-area'), ('and', 'dosage'), ('social effects', 'dosage'), ('of', 'application-area'), ('MDMA in humans.', 'dosage'), ('the OXTR (', 'application-area'), (',', 'dosage'), (')', 'dosage'), ('on', 'application-area'), ('the emotional', 'application-area'), (', empathogenic', 'dosage'), (',', 'dosage'), ('and', 'dosage'), ('prosocial effects', 'dosage'), ('of', 'application-area'), ('MDMA', 'dosage'), ('were characterized in', 'application-area'), ('up to', 'dosage'), ('healthy', 'application-area'), ('in', 'application-area'), ('a pooled analysis', 'application-area'), ('of eight double', 'application-area'), ('-blind', 'application-area'), (',', 'application-area'), ('placebo', 'application-area'), ('In', 'application-area'), ('a subset', 'application-area'), ('of', 'application-area'), ('53 subjects', 'dosage'), (',', 'dosage'), ('MDMA produced significantly greater', 'dosage'), ('feelings of', 'application-area'), ('trust', 'dosage'), ('in', 'application-area'), ('genotypes compared', 'dosage'), ('carriers.', 'dosage'), ('the', 'application-area'), ('subjective effects', 'dosage'), ('of', 'application-area'), ('MDMA in', 'dosage'), ('up to', 'dosage'), ('of', 'application-area'), ('MDMA', 'dosage'), ('-induced impairments in', 'dosage'), ('negative', 'application-area'), ('facial', 'application-area'), ('emotion', 'dosage'), ('recognition or enhancements', 'dosage'), ('in emotional empathy in', 'dosage'), ('in', 'dosage'), ('69 subjects.', 'dosage'), ('MDMA significantly increased plasma oxytocin', 'dosage'), ('concentrations.', 'dosage'), ('MDMA', 'dosage'), ('and oxytocin', 'dosage'), ('concentrations did not differ between OXTR', 'dosage'), ('provide preliminary', 'application-area'), ('evidence', 'dosage'), ('that OXTR', 'application-area'), ('aspects', 'dosage'), ('of', 'dosage'), ('the', 'application-area'), ('prosocial', 'dosage'), ('subjective effects', 'dosage'), ('of', 'application-area'), ('MDMA in humans. However', 'application-area'), (',', 'dosage'), ('interpretation', 'dosage'), ('should', 'application-area'), ('be', 'application-area'), ('cautious due', 'dosage'), ('small', 'application-area'), (', OXTR', 'application-area'), ('subjective overall', 'dosage'), ('effect of', 'dosage'), ('MDMA (', 'dosage'), ('any', 'dosage'), ('drug', 'dosage'), ('effect', 'dosage'), (')', 'dosage'), ('or', 'dosage'), ('""closeness', 'dosage'), ('to', 'application-area'), ('.', 'application-area'), ('TRIAL', 'application-area'), ('REGISTRATION', 'application-area'), (': ClinicalTrials.gov', 'application-area'), (':', 'application-area'), ('http://www.clinicaltrials.gov', 'application-area'), (',', 'application-area'), (':', 'application-area'), ('NCT00886886', 'application-area'), (',', 'application-area'), ('NCT00990067', 'dosage'), (',', 'application-area'), ('NCT01136278', 'dosage'), ('NCT01270672', 'dosage'), ('NCT01386177', 'dosage'), (',', 'application-area'), ('NCT01465685', 'dosage'), ('NCT01771874', 'dosage'), ('and', 'application-area')]"
941,"['Psilocybin', '’s', 'effects', 'on', 'cognition', 'and', 'creativity', ':', 'A', 'scoping', 'review.^', '\n', 'Background', ':', 'Research', 'on', 'psilocybin', 'has', 'become', 'increasingly', 'popular', 'during', 'the', 'current', 'psychedelic', 'renaissance', ',', 'which', 'began', 'in', 'the', 'early', '1990s', '.', 'Psilocybin', '’s', 'effects', 'on', 'mental', 'health', 'are', 'promising', 'and', 'there', 'are', 'ongoing', 'efforts', 'to', 'investigate', 'its', 'clinical', 'implementation', 'and', 'its', 'effects', 'on', 'cognition', '.', 'Aims', ':', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'report', 'trends', 'in', 'publications', ',', 'methods', ',', 'and', 'findings', 'from', 'research', 'examining', 'the', 'effects', 'of', 'psilocybin', 'on', 'cognition', 'and', 'creativity', 'in', 'adults', '.', 'Methods', ':', 'We', 'conducted', 'an', 'Open', 'Science', 'Framework', 'preregistered', 'scoping', 'review', ',', 'guided', 'by', 'the', 'JBI', 'Manual', 'for', 'Evidence', 'Synthesis', ',', 'on', 'literature', 'pertaining', 'to', 'psilocybin', '’s', 'effects', 'on', 'cognition', 'and', 'creativity', '.', 'Results', '/', 'outcomes', ':', 'In', 'the', '42', 'included', 'studies', ',', 'psilocybin', 'was', 'primarily', 'administered', 'orally', '(', '83', '%', ')', 'in', 'a', 'bodyweight', '-', 'adjusted', 'manner', '(', '74', '%', ')', 'to', 'healthy', 'participants', '(', '90', '%', ')', '.', 'Of', 'the', 'few', 'studies', 'that', 'explicitly', 'reported', 'safety', 'outcomes', '(', '26', '%', ')', ',', 'only', 'one', 'reported', 'serious', 'adverse', 'reactions', '.', 'During', 'the', 'acute', 'phase', 'post', '-', 'intake', '(', 'i.e.', ',', 'minutes', 'to', 'hours', ')', ',', 'macrodoses', 'tended', 'to', 'impair', 'cognitive', 'performance', 'and', 'creativity', ',', 'whereas', 'microdoses', 'tended', 'toward', 'creative', 'enhancement', '.', 'The', 'few', 'macrodosing', 'studies', 'that', 'included', 'post', '-', 'acute', 'measures', '(', 'i.e.', ',', '1–85', 'days', ')', 'reported', 'primarily', 'null', 'but', 'some', 'positive', 'effects', '.', 'Conclusions', '/', 'interpretation', ':', 'This', 'scoping', 'review', 'identified', 'a', 'time', '-', 'based', 'variation', 'of', 'psilocybin', 'macrodosing', 'effects', 'on', 'cognition', 'and', 'creativity', ',', 'in', 'which', 'impairment', 'may', 'be', 'observed', 'early', 'post', '-', 'intake', 'but', 'withdraw', 'over', 'time', ',', 'and', 'some', 'positive', 'effects', 'may', 'emerge', 'afterward', '.', 'These', 'findings', 'are', 'limited', 'by', 'methodological', 'concerns', 'and', 'inadequate', 'assessment', 'of', 'long', '-', 'term', 'effects', '.', 'We', 'therefore', 'recommend', 'that', 'future', 'psilocybin', 'research', 'be', 'conducted', 'according', 'to', 'existing', 'guidelines', 'and', 'include', 'well', '-', 'validated', 'measures', 'of', 'cognition', 'and', 'creativity', 'at', 'multiple', 'timepoints', '.']","['I-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'B-Application area', 'I-Dosage', 'B-Application area', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'B-Application area', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'B-Dosage', 'B-Application area', 'B-Dosage', 'B-Dosage', 'O', 'B-Dosage', 'O', 'I-Dosage', 'I-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Application area', 'B-Dosage', 'B-Application area', 'B-Dosage', 'B-Dosage', 'B-Application area', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Application area', 'B-Dosage', 'I-Application area', 'I-Application area', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'I-Application area', 'I-Dosage', 'B-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'I-Application area', 'B-Application area', 'I-Dosage', 'B-Dosage', 'B-Application area', 'I-Dosage', 'B-Dosage', 'I-Dosage', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'B-Application area', 'B-Application area', 'B-Application area', 'B-Dosage', 'O', 'I-Application area', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'B-Application area', 'B-Application area', 'B-Application area', 'B-Application area', 'B-Dosage', 'B-Application area', 'B-Dosage', 'B-Dosage', 'I-Dosage', 'B-Dosage', 'B-Application area', 'B-Application area', 'B-Application area', 'B-Application area', 'B-Dosage', 'B-Application area', 'I-Dosage', 'I-Application area', 'B-Dosage', 'B-Application area', 'B-Dosage', 'I-Dosage', 'B-Application area', 'I-Application area', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'I-Application area', 'I-Dosage', 'I-Dosage', 'B-Application area', 'O', 'O', 'B-Application area', 'I-Dosage', 'B-Dosage', 'I-Application area', 'B-Application area', 'B-Dosage', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'I-Application area', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'B-Dosage', 'I-Dosage', 'B-Dosage', 'B-Application area', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Dosage', 'B-Dosage', 'O', 'O', 'O', 'B-Application area', 'I-Dosage', 'B-Application area', 'I-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'I-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'I-Dosage', 'B-Dosage', 'O', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'I-Application area', 'I-Dosage', 'B-Application area', 'I-Dosage', 'B-Application area', 'I-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'I-Application area', 'O', 'O', 'I-Dosage', 'B-Application area', 'I-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Application area', 'B-Application area', 'B-Dosage', 'I-Application area', 'I-Application area', 'B-Dosage', 'B-Dosage', 'O', 'I-Dosage', 'B-Dosage', 'I-Application area', 'I-Application area', 'B-Dosage', 'B-Dosage', 'O', 'O', 'B-Dosage', 'I-Dosage', 'B-Application area', 'O', 'I-Application area', 'B-Dosage', 'B-Application area', 'I-Dosage', 'I-Application area', 'B-Dosage', 'B-Dosage', 'O', 'I-Dosage', 'B-Dosage', 'I-Dosage', 'B-Dosage', 'B-Dosage', 'I-Application area', 'O', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Application area', 'I-Dosage', 'B-Dosage', 'O', 'O', 'B-Dosage', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'B-Dosage', 'B-Application area', 'I-Application area', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'I-Application area', 'B-Application area', 'I-Application area', 'B-Application area', 'I-Application area', 'B-Dosage', 'I-Application area', 'B-Dosage', 'B-Dosage', 'B-Application area', 'B-Application area', 'B-Application area', 'I-Application area', 'B-Dosage', 'B-Dosage', 'O', 'B-Dosage', 'B-Application area', 'B-Application area', 'B-Dosage', 'B-Application area', 'I-Dosage', 'O', 'I-Dosage', 'O', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Dosage', 'I-Application area', 'B-Dosage', 'I-Dosage', 'O', 'O', 'B-Dosage', 'B-Dosage', 'I-Application area', 'I-Dosage', 'B-Application area', 'I-Application area', 'B-Application area', 'B-Application area', 'B-Application area', 'I-Application area', 'B-Dosage', 'B-Application area', 'B-Application area', 'B-Dosage', 'B-Application area', 'I-Application area', 'B-Dosage', 'B-Dosage', 'B-Application area', 'B-Application area', 'O', 'B-Dosage', 'I-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Application area', 'B-Application area', 'I-Dosage']","Psilocybin’s effects on cognition and creativity: A scoping review.^
Background: Research on psilocybin has become increasingly popular during the current psychedelic renaissance, which began in the early 1990s. Psilocybin’s effects on mental health are promising and there are ongoing efforts to investigate its clinical implementation and its effects on cognition. Aims: The purpose of this study is to report trends in publications, methods, and findings from research examining the effects of psilocybin on cognition and creativity in adults. Methods: We conducted an Open Science Framework preregistered scoping review, guided by the JBI Manual for Evidence Synthesis, on literature pertaining to psilocybin’s effects on cognition and creativity. Results/outcomes: In the 42 included studies, psilocybin was primarily administered orally (83%) in a bodyweight-adjusted manner (74%) to healthy participants (90%). Of the few studies that explicitly reported safety outcomes (26%), only one reported serious adverse reactions. During the acute phase post-intake (i.e., minutes to hours), macrodoses tended to impair cognitive performance and creativity, whereas microdoses tended toward creative enhancement. The few macrodosing studies that included post-acute measures (i.e., 1–85 days) reported primarily null but some positive effects. Conclusions/interpretation: This scoping review identified a time-based variation of psilocybin macrodosing effects on cognition and creativity, in which impairment may be observed early post-intake but withdraw over time, and some positive effects may emerge afterward. These findings are limited by methodological concerns and inadequate assessment of long-term effects. We therefore recommend that future psilocybin research be conducted according to existing guidelines and include well-validated measures of cognition and creativity at multiple timepoints.","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",[],"[('’s', 'dosage'), ('effects', 'dosage'), ('on', 'dosage'), ('cognition', 'dosage'), ('and', 'dosage'), ('creativity: A', 'dosage'), ('scoping review.^ Background: Research', 'dosage'), ('on psilocybin', 'application-area'), ('has', 'application-area'), ('become increasingly popular', 'dosage'), ('during', 'application-area'), ('current psychedelic renaissance', 'application-area'), (',', 'dosage'), ('which', 'application-area'), ('began', 'dosage'), ('in', 'dosage'), ('early', 'dosage'), ('’s', 'dosage'), ('effects', 'dosage'), ('on', 'dosage'), ('mental', 'application-area'), ('health', 'dosage'), ('are', 'application-area'), ('promising', 'dosage'), ('and', 'dosage'), ('there', 'application-area'), ('are', 'dosage'), ('ongoing', 'dosage'), ('efforts', 'dosage'), ('to', 'application-area'), ('investigate its clinical', 'dosage'), ('implementation', 'dosage'), ('and', 'dosage'), ('its', 'dosage'), ('effects', 'dosage'), ('on', 'dosage'), ('cognition', 'dosage'), ('. Aims:', 'dosage'), ('The purpose', 'application-area'), ('this', 'application-area'), ('to report', 'application-area'), ('trends', 'dosage'), ('in publications', 'application-area'), (', methods', 'dosage'), (', and findings', 'dosage'), ('research', 'application-area'), ('examining', 'application-area'), ('the', 'application-area'), ('effects', 'dosage'), ('on', 'dosage'), ('cognition', 'dosage'), ('and', 'dosage'), ('creativity', 'dosage'), ('in', 'dosage'), ('. Methods:', 'dosage'), ('We', 'application-area'), ('conducted', 'application-area'), ('an', 'application-area'), ('Open', 'application-area'), ('Science', 'dosage'), ('Framework', 'application-area'), ('preregistered', 'dosage'), ('scoping review', 'dosage'), (',', 'dosage'), ('guided', 'application-area'), ('by', 'application-area'), ('the', 'application-area'), ('JBI', 'application-area'), ('Manual', 'dosage'), ('for Evidence Synthesis', 'application-area'), (',', 'dosage'), ('on', 'application-area'), ('literature pertaining', 'dosage'), ('to psilocybin', 'application-area'), ('’s', 'dosage'), ('effects', 'dosage'), ('on', 'dosage'), ('cognition', 'dosage'), ('and', 'dosage'), ('creativity', 'dosage'), ('.', 'dosage'), ('Results/outcomes:', 'dosage'), ('In', 'application-area'), ('included studies', 'application-area'), (', psilocybin', 'dosage'), ('was', 'application-area'), ('primarily', 'dosage'), ('administered orally (', 'dosage'), ('%', 'dosage'), (')', 'dosage'), ('in a', 'dosage'), ('adjusted manner (', 'dosage'), ('74%', 'dosage'), (')', 'dosage'), ('to', 'application-area'), ('healthy participants (', 'application-area'), ('%', 'dosage'), (')', 'dosage'), ('few studies', 'application-area'), ('that explicitly', 'application-area'), ('reported', 'dosage'), ('safety', 'dosage'), ('outcomes (', 'dosage'), ('26', 'dosage'), ('%', 'dosage'), ('),', 'dosage'), ('only', 'dosage'), ('reported', 'dosage'), ('serious', 'dosage'), ('adverse reactions.', 'dosage'), ('During the', 'application-area'), ('acute phase', 'application-area'), ('post', 'dosage'), ('-', 'dosage'), ('intake (', 'dosage'), ('to hours', 'application-area'), (')', 'dosage'), (',', 'dosage'), ('macrodoses', 'dosage'), ('tended', 'dosage'), ('to', 'application-area'), ('impair', 'application-area'), ('cognitive performance and', 'dosage'), ('creativity', 'dosage'), (',', 'dosage'), ('tended toward creative', 'dosage'), ('enhancement', 'dosage'), ('.', 'dosage'), ('macrodosing studies', 'dosage'), ('that', 'application-area'), ('-', 'dosage'), ('acute measures (', 'application-area'), ('i.e.', 'dosage'), (',', 'dosage'), (') reported', 'dosage'), ('primarily', 'dosage'), ('null but', 'dosage'), ('positive', 'dosage'), ('effects', 'dosage'), ('.', 'dosage'), ('Conclusions/', 'application-area'), ('interpretation', 'dosage'), ('scoping', 'dosage'), ('a time-', 'dosage'), ('variation', 'dosage'), ('of psilocybin', 'application-area'), ('macrodosing', 'dosage'), ('effects', 'dosage'), ('on', 'dosage'), ('cognition', 'dosage'), ('and', 'dosage'), ('creativity', 'dosage'), (',', 'dosage'), ('in which', 'dosage'), ('impairment may', 'application-area'), ('be observed', 'application-area'), ('early post', 'dosage'), ('-', 'dosage'), ('intake', 'dosage'), ('but', 'application-area'), ('withdraw', 'application-area'), ('over time', 'application-area'), (',', 'dosage'), ('and', 'dosage'), ('positive', 'dosage'), ('effects', 'application-area'), ('may', 'application-area'), ('emerge', 'dosage'), ('afterward.', 'application-area'), ('inadequate assessment', 'dosage'), ('-', 'dosage'), ('term effects.', 'dosage'), ('We therefore', 'application-area'), ('recommend', 'application-area'), ('that', 'application-area'), ('future psilocybin', 'application-area'), ('research', 'dosage'), ('be', 'application-area'), ('conducted', 'application-area'), ('according', 'dosage'), ('to existing', 'application-area'), ('guidelines', 'dosage'), ('and', 'dosage'), ('include', 'application-area'), ('well', 'application-area'), ('validated measures', 'dosage'), ('of', 'dosage'), ('cognition', 'dosage'), ('and', 'dosage'), ('creativity', 'dosage'), ('at', 'dosage'), ('multiple', 'application-area')]"
8030,"['Prevalence', 'and', 'associations', 'of', 'challenging', ',', 'difficult', 'or', 'distressing', 'experiences', 'using', 'classic', 'psychedelics.^', '\n', 'Previous', 'studies', 'have', 'investigated', 'challenging', ',', 'difficult', ',', 'or', 'distressing', 'classic', 'psychedelic', 'experiences', ',', 'but', 'little', 'is', 'known', 'about', 'the', 'prevalence', 'and', 'associations', 'of', 'such', 'experiences', '.', 'Using', 'nationally', 'representative', 'data', 'of', 'the', 'US', 'adult', 'population', '(', 'N', '=', '2822', ')', ',', 'this', 'study', 'examined', 'the', 'prevalence', 'and', 'associations', 'of', 'challenging', ',', 'difficult', ',', 'or', 'distressing', 'experiences', 'using', 'classic', 'psychedelics', ',', 'in', 'a', 'subsample', 'of', 'respondents', 'who', 'reported', 'lifetime', 'classic', 'psychedelic', 'use', '(', 'n', '=', '613', ')', '.', 'Of', 'the', '613', 'respondents', 'who', 'reported', 'lifetime', 'classic', 'psychedelic', 'use', ',', 'the', 'majority', 'of', 'them', '(', '59.1', '%', ')', 'had', 'never', 'had', 'a', 'challenging', ',', 'difficult', ',', 'or', 'distressing', 'experience', 'using', 'a', 'classic', 'psychedelic', ',', 'but', '8.9', '%', 'of', 'respondents', 'reported', 'functional', 'impairment', 'that', 'lasted', 'longer', 'than', 'one', 'day', 'as', 'a', 'result', 'of', 'such', 'experiences', '.', 'Notably', ',', '2.6', '%', 'reported', 'seeking', 'medical', ',', 'psychiatric', ',', 'or', 'psychological', 'assistance', 'in', 'the', 'days', 'or', 'weeks', 'following', 'their', 'most', 'challenging', ',', 'difficult', ',', 'or', 'distressing', 'classic', 'psychedelic', 'experience', '.', 'In', 'covariate', '-', 'adjusted', 'regression', 'models', ',', 'co', '-', 'use', 'of', 'lithium', ',', 'co', '-', 'use', 'of', 'other', 'mood', 'stabilizers', ',', 'and', 'six', 'set', 'and', 'setting', 'variables', '(', 'no', 'preparation', ',', 'disagreeable', 'physical', 'environment', ',', 'negative', 'mindset', ',', 'no', 'psychological', 'support', ',', 'dose', 'was', 'too', 'large', ',', 'major', 'life', 'event', 'prior', 'to', 'experience', ')', 'were', 'associated', 'with', 'the', 'degree', 'of', 'difficulty', ';', 'and', 'co', '-', 'use', 'of', 'lithium', ',', 'co', '-', 'use', 'of', 'other', 'mood', 'stabilizers', ',', 'and', 'three', 'set', 'and', 'setting', 'variables', '(', 'negative', 'mindset', ',', 'no', 'psychological', 'support', ',', 'major', 'life', 'event', 'prior', 'to', 'experience', ')', 'were', 'associated', 'with', 'overall', 'risk', 'of', 'harm', '.', 'In', 'summary', ',', 'this', 'study', 'provides', 'insight', 'into', 'the', 'prevalence', 'and', 'associations', 'of', 'challenging', ',', 'difficult', ',', 'or', 'distressing', 'classic', 'psychedelic', 'experiences', '.', 'The', 'findings', 'broadly', 'correspond', 'with', 'findings', 'from', 'previous', 'studies', 'and', 'can', 'inform', 'harm', 'reduction', 'efforts', 'and', 'future', 'experimental', 'research', 'designs', '.']","['I-Application area', 'O', 'B-Dosage', 'I-Application area', 'I-Dosage', 'B-Dosage', 'I-Application area', 'O', 'I-Application area', 'B-Dosage', 'I-Application area', 'B-Dosage', 'I-Application area', 'I-Dosage', 'I-Application area', 'B-Dosage', 'B-Application area', 'O', 'B-Application area', 'B-Dosage', 'I-Application area', 'B-Dosage', 'O', 'I-Application area', 'B-Dosage', 'I-Application area', 'B-Dosage', 'B-Dosage', 'B-Application area', 'O', 'B-Application area', 'B-Application area', 'B-Application area', 'O', 'B-Dosage', 'O', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'I-Dosage', 'O', 'B-Dosage', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'B-Application area', 'I-Dosage', 'O', 'B-Application area', 'O', 'B-Application area', 'I-Application area', 'O', 'B-Dosage', 'O', 'B-Dosage', 'B-Dosage', 'B-Application area', 'B-Dosage', 'I-Application area', 'B-Dosage', 'O', 'I-Application area', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'I-Application area', 'B-Dosage', 'B-Application area', 'B-Dosage', 'I-Application area', 'B-Application area', 'I-Application area', 'O', 'O', 'O', 'B-Dosage', 'I-Application area', 'O', 'O', 'B-Dosage', 'I-Dosage', 'B-Dosage', 'B-Dosage', 'I-Dosage', 'I-Application area', 'I-Dosage', 'B-Application area', 'I-Application area', 'B-Application area', 'B-Application area', 'O', 'B-Dosage', 'I-Application area', 'I-Application area', 'B-Dosage', 'O', 'B-Dosage', 'I-Application area', 'B-Dosage', 'I-Dosage', 'B-Dosage', 'B-Dosage', 'O', 'B-Application area', 'O', 'I-Dosage', 'B-Dosage', 'B-Application area', 'B-Dosage', 'I-Dosage', 'B-Dosage', 'B-Application area', 'I-Application area', 'O', 'I-Dosage', 'B-Dosage', 'B-Dosage', 'I-Application area', 'B-Dosage', 'B-Application area', 'B-Dosage', 'B-Dosage', 'B-Application area', 'I-Application area', 'B-Dosage', 'I-Application area', 'B-Application area', 'B-Application area', 'I-Dosage', 'B-Dosage', 'B-Dosage', 'O', 'B-Dosage', 'I-Dosage', 'B-Application area', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Application area', 'B-Application area', 'I-Application area', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'O', 'B-Dosage', 'O', 'B-Application area', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Dosage', 'B-Dosage', 'I-Dosage', 'B-Dosage', 'B-Application area', 'I-Application area', 'B-Dosage', 'I-Application area', 'I-Application area', 'I-Dosage', 'O', 'I-Dosage', 'O', 'O', 'I-Application area', 'I-Application area', 'B-Dosage', 'O', 'B-Dosage', 'B-Dosage', 'B-Application area', 'O', 'B-Dosage', 'O', 'B-Dosage', 'I-Dosage', 'I-Application area', 'B-Application area', 'I-Dosage', 'I-Dosage', 'B-Dosage', 'B-Application area', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'O', 'O', 'B-Dosage', 'O', 'B-Dosage', 'B-Dosage', 'B-Application area', 'B-Application area', 'O', 'B-Dosage', 'B-Application area', 'B-Dosage', 'B-Dosage', 'B-Application area', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Application area', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Application area', 'B-Dosage', 'B-Dosage', 'B-Application area', 'B-Dosage', 'B-Dosage', 'O', 'I-Application area', 'B-Dosage', 'O', 'B-Dosage', 'O', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'O', 'B-Dosage', 'B-Dosage', 'B-Application area', 'O', 'B-Dosage', 'O', 'B-Dosage', 'I-Dosage', 'I-Application area', 'B-Application area', 'I-Dosage', 'I-Dosage', 'B-Dosage', 'B-Application area', 'B-Application area', 'B-Dosage', 'B-Dosage', 'O', 'O', 'B-Dosage', 'O', 'B-Dosage', 'B-Dosage', 'B-Application area', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'B-Dosage', 'I-Application area', 'B-Dosage', 'B-Dosage', 'B-Application area', 'B-Dosage', 'B-Dosage', 'O', 'I-Application area', 'O', 'O', 'B-Application area', 'B-Dosage', 'B-Application area', 'I-Dosage', 'B-Application area', 'I-Dosage', 'B-Dosage', 'I-Application area', 'O', 'B-Dosage', 'I-Application area', 'B-Application area', 'O', 'I-Application area', 'O', 'B-Dosage', 'B-Dosage', 'B-Application area', 'B-Dosage', 'I-Application area', 'B-Dosage', 'O', 'I-Application area', 'B-Dosage', 'I-Application area', 'B-Dosage', 'I-Dosage', 'O', 'I-Application area', 'I-Application area', 'B-Dosage', 'B-Dosage', 'I-Dosage', 'O', 'I-Application area', 'I-Dosage', 'I-Application area', 'I-Application area', 'I-Application area', 'B-Dosage', 'I-Application area', 'B-Dosage', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'B-Dosage', 'I-Dosage']","Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics.^
Previous studies have investigated challenging, difficult, or distressing classic psychedelic experiences, but little is known about the prevalence and associations of such experiences. Using nationally representative data of the US adult population (N = 2822), this study examined the prevalence and associations of challenging, difficult, or distressing experiences using classic psychedelics, in a subsample of respondents who reported lifetime classic psychedelic use (n = 613). Of the 613 respondents who reported lifetime classic psychedelic use, the majority of them (59.1 %) had never had a challenging, difficult, or distressing experience using a classic psychedelic, but 8.9 % of respondents reported functional impairment that lasted longer than one day as a result of such experiences. Notably, 2.6 % reported seeking medical, psychiatric, or psychological assistance in the days or weeks following their most challenging, difficult, or distressing classic psychedelic experience. In covariate-adjusted regression models, co-use of lithium, co-use of other mood stabilizers, and six set and setting variables (no preparation, disagreeable physical environment, negative mindset, no psychological support, dose was too large, major life event prior to experience) were associated with the degree of difficulty; and co-use of lithium, co-use of other mood stabilizers, and three set and setting variables (negative mindset, no psychological support, major life event prior to experience) were associated with overall risk of harm. In summary, this study provides insight into the prevalence and associations of challenging, difficult, or distressing classic psychedelic experiences. The findings broadly correspond with findings from previous studies and can inform harm reduction efforts and future experimental research designs.","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",[],"[('associations of challenging', 'dosage'), (', difficult', 'dosage'), ('experiences using', 'dosage'), ('classic psychedelics.^ Previous', 'dosage'), ('studies', 'dosage'), ('have', 'application-area'), ('challenging', 'application-area'), (', difficult', 'dosage'), (',', 'dosage'), ('classic psychedelic', 'dosage'), ('experiences', 'dosage'), (',', 'dosage'), ('but', 'application-area'), ('is', 'application-area'), ('known', 'application-area'), ('about', 'application-area'), ('prevalence', 'dosage'), ('associations', 'dosage'), ('of', 'dosage'), ('such', 'dosage'), ('experiences.', 'dosage'), ('nationally', 'dosage'), ('data', 'application-area'), ('population (N', 'application-area'), ('= 2822', 'application-area'), (',', 'application-area'), ('study examined', 'application-area'), ('prevalence', 'dosage'), ('associations', 'dosage'), ('of', 'dosage'), ('challenging', 'application-area'), (', difficult', 'dosage'), (',', 'dosage'), ('experiences', 'dosage'), ('using', 'dosage'), ('classic psychedelics', 'dosage'), (',', 'dosage'), ('in', 'application-area'), ('a subsample', 'dosage'), ('of respondents', 'application-area'), ('classic psychedelic', 'dosage'), ('n =', 'dosage'), ('613', 'dosage'), ('). Of the', 'dosage'), ('613 respondents', 'application-area'), ('who', 'application-area'), ('reported', 'application-area'), ('classic psychedelic use', 'dosage'), (',', 'dosage'), ('majority of', 'dosage'), ('them (', 'dosage'), ('59.1', 'dosage'), ('%', 'dosage'), ('had', 'application-area'), ('a', 'dosage'), ('challenging', 'application-area'), (', difficult', 'dosage'), (',', 'dosage'), ('or distressing', 'application-area'), ('a', 'dosage'), ('classic psychedelic', 'dosage'), (',', 'dosage'), ('but', 'application-area'), ('8.9', 'dosage'), ('%', 'dosage'), ('of respondents', 'application-area'), ('reported functional', 'dosage'), ('impairment', 'application-area'), ('that lasted', 'application-area'), ('longer', 'dosage'), ('than', 'dosage'), ('day as', 'dosage'), ('a', 'application-area'), ('result', 'dosage'), ('of', 'dosage'), ('such', 'dosage'), ('experiences. Notably', 'dosage'), (',', 'dosage'), ('2.6', 'dosage'), ('%', 'dosage'), ('reported', 'application-area'), ('seeking medical', 'application-area'), (',', 'dosage'), ('psychiatric', 'dosage'), (',', 'dosage'), ('or', 'dosage'), ('psychological', 'dosage'), ('assistance', 'dosage'), ('in', 'dosage'), ('days', 'dosage'), ('weeks', 'application-area'), ('following their most challenging', 'application-area'), (', difficult', 'dosage'), (',', 'dosage'), ('or distressing', 'application-area'), ('classic psychedelic experience.', 'dosage'), (',', 'dosage'), ('-', 'dosage'), ('use', 'dosage'), ('of', 'application-area'), (',', 'dosage'), ('-use of', 'dosage'), ('other mood stabilizers', 'application-area'), (',', 'dosage'), ('and', 'application-area'), ('six', 'dosage'), ('set', 'dosage'), ('and', 'dosage'), ('(', 'dosage'), ('preparation', 'dosage'), (',', 'dosage'), ('disagreeable', 'application-area'), ('physical', 'application-area'), (',', 'dosage'), ('negative', 'application-area'), ('mindset', 'dosage'), (',', 'dosage'), ('no', 'application-area'), ('psychological', 'dosage'), ('support', 'dosage'), (',', 'dosage'), ('dose', 'dosage'), ('was', 'dosage'), ('too', 'application-area'), ('large', 'dosage'), (',', 'dosage'), ('major', 'dosage'), ('life', 'application-area'), ('event', 'dosage'), ('prior', 'dosage'), ('to', 'application-area'), ('experience', 'dosage'), (')', 'dosage'), ('with', 'dosage'), ('degree', 'dosage'), ('difficulty', 'dosage'), (';', 'dosage'), ('and', 'dosage'), ('-', 'dosage'), ('use', 'dosage'), ('of', 'application-area'), (',', 'dosage'), ('-use of', 'dosage'), ('other mood stabilizers', 'application-area'), (',', 'dosage'), ('and', 'application-area'), ('three', 'application-area'), ('set', 'dosage'), ('and', 'dosage'), ('(', 'dosage'), ('mindset', 'dosage'), (',', 'dosage'), ('no', 'application-area'), ('psychological', 'dosage'), ('support', 'dosage'), (',', 'dosage'), ('major life', 'dosage'), ('event', 'dosage'), ('prior', 'dosage'), ('to', 'application-area'), ('experience', 'dosage'), (')', 'dosage'), ('risk', 'application-area'), ('of', 'dosage'), ('harm.', 'application-area'), ('In summary', 'application-area'), (', this', 'dosage'), ('provides insight', 'dosage'), ('into', 'application-area'), ('associations', 'dosage'), ('of', 'dosage'), ('challenging', 'application-area'), (', difficult', 'dosage'), (',', 'dosage'), ('classic psychedelic', 'dosage'), ('experiences.', 'dosage'), ('correspond', 'dosage'), ('with findings', 'dosage'), ('harm reduction', 'dosage'), ('efforts and future experimental research', 'dosage')]"
